- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT01477359
Сердечный саркоидоз Многоцентровая проспективная когорта (CHASM-CS)
Многоцентровое проспективное когортное исследование сердечного саркоидоза
Recent data has shown that sarcoidosis, presenting initially with cardiac manifestations (CS) of either conduction system disease or cardiomyopathy and sustained VT, is not uncommon. A Canadian physician survey found that most physicians do not investigate for CS as a possibility in these situations. Thus many patients with clinically important CS are going un-diagnosed. A study from Finland showed that missing the diagnosis of CS in these patients' leads to significant mortality and morbidity.
There are no published clinical consensus guidelines on treatment of CS. Corticosteroid therapy is advocated by most experts. This is based on very modest data from small retrospective observational studies using variable definitions of clinical response. The effect of corticosteroid treatment on the clinical course of CS has not been studied in prospective studies and will be one of the aims of this project. Recent physician surveys regarding CS, in Canada and the US, found that current clinical practice varies widely. The 2008 American College of Cardiology/American Heart Association/Heart Rhythm society guidelines recommend implantation of a defibrillator (Class IIa recommendation) to prevent sudden cardiac death. The most recent Canadian device therapy guidelines do not mention CS.
A multi-center collaborative approach to study CS is greatly needed." The investigators propose exactly that i.e. a multi-center prospective cohort to start to answer clinical questions. The investigators have formed the CANADIAN CARDIAC SARCOIDOSIS RESEARCH GROUP. The group includes respirologists with an interest in sarcoidosis, cardiac electrophysiologists, cardiac imaging specialists with extensive experience in imaging of sarcoidosis and biostatisticians. The research will be in two phases; a registry of current diagnostic approaches, treatment and prognosis, and a randomized clinical trial of the effect of corticosteroid treatment on the clinical course of cardiac sarcoidosis.
Обзор исследования
Статус
Условия
Подробное описание
Baseline assessment of Clinically Manifest CS patients consists of: history, echocardiogram, ECG, chest CT scan, FDG-PET scan, blood for biomarkers within 2 months of the PET scan, cardiac MRI and possibly a signal average ECG and biopsy (encouraged-either endomyocardial or extra-cardiac).
Follow-up and clinical management of clinically manifest patients diagnosed with CS will occur at 3-6 months with a repeat FDG-PET scan and blood biomarkers. Follow-up will then be annually with an echo and ECG. Treatment with steroids/immunosuppressants and device therapy will be at the discretion of the treating physician.
Baseline assessment of patients diagnosed with extra-cardiac sarcoidosis and being screened for CS consists of: history, echocardiogram, ECG, holter, chest CT scan, biopsy, and cardiac MRI (CMR). If the CMR is suggestive of CS the patient will be have a FDG-PET scan done and be followed as a Clinically Silent patient. They will be contacted every 2 years. If the CMR is negative the patient will be followed as a extra-cardiac sarcoidosis patient with no evidence of CS and be in the control group. They will be contacted at 5 years and at the time of study completion.
All patients will be followed until the last patient recruited has been followed for 4 years.
The occurrence of the primary and secondary outcomes will be assessed in treated and untreated patients.
There will be 2 imaging core labs. The PET core lab will be located at UOHI under the direction of Dr. Robert Beanlands. The CMR core lab will be under the direction of Dr. Mathias Friedrich (McGill University). All scans will be read in the core labs by physicians who are blinded to the clinical details of the patients.
The Biomarker core lab will be at The University of Ottawa Heart Institute under the leadership of Dr P Liu.
Тип исследования
Регистрация (Оцененный)
Контакты и местонахождение
Контакты исследования
- Имя: Janine E Ryan, BA(H), CCRP
- Номер телефона: 17077 613-696-7000
- Электронная почта: jryan@ottawaheart.ca
Учебное резервное копирование контактов
- Имя: David Birnie, MD
- Номер телефона: 613-696-7269
- Электронная почта: dbirnie@ottawaheart.ca
Места учебы
-
-
Alberta
-
Calgary, Alberta, Канада, T2N 2T9
- Рекрутинг
- Libin Cardiovascular Institute of Alberta
-
Главный следователь:
- Russell Quinn, MD
-
Контакт:
- Russell Quinn, MD
-
Edmonton, Alberta, Канада, T6G 2B7
- Рекрутинг
- University of Alberta Hospital
-
Контакт:
- Tomascz Hruczkowski, MD
-
Главный следователь:
- Tomascz Hruczkowski, MD
-
-
British Columbia
-
Vancouver, British Columbia, Канада, V5Z 1M9
- Рекрутинг
- St. Paul's Hospital
-
Контакт:
- Shanta Chakrabarti, MD
-
Главный следователь:
- Shanta Chakrabarti, MD
-
-
Nova Scotia
-
Halifax, Nova Scotia, Канада, B3H 3A7
- Рекрутинг
- QEII Health Sciences Center
-
Главный следователь:
- Ciorsti MacIntyre, MD
-
Контакт:
- Kim Anderson, MD
-
-
Ontario
-
Hamilton, Ontario, Канада, L8L 2X2
- Рекрутинг
- Hamilton Health Sciences Centre
-
Главный следователь:
- Jeff Healey, MD
-
Контакт:
- Gerard Cox, MD
-
Контакт:
- Jeff Healey, MD
-
London, Ontario, Канада, N6A 5A5
- Рекрутинг
- London Health Sciences Centre
-
Контакт:
- Lorne Gula, MD
-
Главный следователь:
- Lorne Gula, MD
-
Newmarket, Ontario, Канада, L3Y 2P9
- Рекрутинг
- Southlake Regional Health Centre
-
Контакт:
- Bernice Tsang, MD
-
Главный следователь:
- Bernice Tsang, MD
-
Ottawa, Ontario, Канада, K1Y 4W7
- Рекрутинг
- University of Ottawa Heart Institute
-
Контакт:
- Tammy Knight
- Номер телефона: 19080 613-696-7000
- Электронная почта: tknight@ottawaheart.ca
-
Главный следователь:
- David Birnie, MD
-
Контакт:
- Janine E Ryan, BA H
- Номер телефона: 17077 613-696-7000
- Электронная почта: jryan@ottawaheart.ca
-
Toronto, Ontario, Канада, M5G 2C4
- Рекрутинг
- Toronto General Hospital
-
Контакт:
- Andrew Ha, MD
-
Главный следователь:
- Andrew Ha, MD
-
-
Quebec
-
Montreal, Quebec, Канада, H1T 1C8
- Рекрутинг
- Montreal Heart Institute
-
Контакт:
- Lena Rivard, MD
-
Главный следователь:
- Lena Rivard, MD
-
Montreal, Quebec, Канада, H3G 1A4
- Рекрутинг
- McGill University Health Centre
-
Контакт:
- Fiorella Rafti
-
Главный следователь:
- Martin L Bernier, MD
-
Montreal, Quebec, Канада, H2W 1T8
- Еще не набирают
- Centre Hospitalier de l"Universite de Montreal-Hotel Dieu
-
Контакт:
- Julie Fleury, RN
-
Главный следователь:
- Benoit Coutu, MD
-
-
Saskatchewan
-
Regina, Saskatchewan, Канада, S4P 0W5
- Рекрутинг
- Prairie Vascular Research Inc-Regina General Hospital
-
Контакт:
- Kendra Townsend
- Электронная почта: Ktownsend.pvri@gmail.com
-
Главный следователь:
- Andrea Lavoie, MD
-
-
-
-
-
Sapporo, Япония, 060-8638
- Рекрутинг
- Hokkaido University
-
Контакт:
- Ichizo Tsujino, MD
- Номер телефона: 81-11-706-5911
- Электронная почта: itsujino@med.hokudai.ac.jp
-
Главный следователь:
- Ichizo Tsujino, MD
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Метод выборки
Исследуемая популяция
Electrophysiology Service patients
Описание
Inclusion Criteria:
To diagnose Clinically Manifest CS all following criteria must be met:
(i) Positive biopsy* for Sarcoid (either EMB or extra-cardiac) AND/OR (ii) CT Chest highly suggestive of pulmonary sarcoidosis AND (iii) one or more of the following clinical features:
- advanced conduction system disease (sustained Mobitz II AV block or third degree AV block)
- non- sustained or sustained ventricular arrhythmia
- ventricular dysfunction (LVEF < 50% and/or RVEF < 40%) AND (iv) No alternative explanation for clinical features AND (v) FDG-PET suggestive of active CS
To diagnose clinically silent CS all of the following criteria must be met
(i) Biopsy proven extra-cardiac sarcoidosis
AND/OR (ii) CT Chest highly suggestive of pulmonary sarcoidosis
AND (iii) CMR suggestive of cardiac sarcoidosis
AND (iv) Does not have criteria for clinically manifest CS ie. should not have any of following
- advanced conduction system disease (sustained Mobitz II AV block or third degree AV block)
- non- sustained or sustained ventricular arrhythmia
- ventricular dysfunction (LVEF < 50% and/or RVEF < 40%)
Patients with negative CMR will be designated as 'extra-cardiac sarcoidosis with no evidence of CS' and followed as control
Exclusion Criteria:
- unable or unwilling to provide informed consent
- patients who are pregnant or lactating
- patients with known claustrophobia
- age < 18 years
Учебный план
Как устроено исследование?
Детали дизайна
- Наблюдательные модели: COHORT
- Временные перспективы: PROSPECTIVE
Когорты и вмешательства
Группа / когорта |
|---|
|
CS screened as underlying etiology
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Primary Outcome for ALL Patients
Временное ограничение: Through study completion, on average 10 years
|
The primary outcome is a composite of cardiac death, aborted sudden cardiac death, sustained ventricular arrhythmia, heart failure hospitalization or cardiac transplantation. Heart failure hospitalization is defined as admission to hospital > 24 hours and received treatment for heart failure. Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Secondary Outcomes for ALL Patients
Временное ограничение: Through study completion, on average 10 years
|
1. Total mortality Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for ALL Patients
Временное ограничение: Through study completion, on average 10 years
|
2. Individual components of primary outcome (cardiac death, aborted sudden cardiac death, sustained ventricular arrhythmia, heart failure hospitalization or cardiac transplantation) Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for Patients with Clinically Manifest Disease
Временное ограничение: Through study completion, on average 10 years
|
1. Change in LVEF from baseline (%) Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for Patients with Clinically Manifest Disease
Временное ограничение: Through study completion, on average 10 years
|
2. Change in RVEF from baseline (%) Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for Patients with Clinically Manifest Disease
Временное ограничение: Through study completion, on average 10 years
|
3. Change in cardiac disease activity from pre-treatment to on treatment and post-treatment cessation as assessed by FDG-PET Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for Patients with Clinically Manifest Disease
Временное ограничение: Through study completion, on average 10 years
|
4. Atrial fibrillation burden (from ICD and/or pacemaker diagnostics) Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for Patients with Clinically Manifest Disease
Временное ограничение: Through study completion, on average 10 years
|
5. Ventricular arrhythmia burden, including PVC burden (from ICD diagnostics and/or pacemaker diagnostics) Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for Patients with Clinically Manifest Disease
Временное ограничение: Through study completion, on average 10 years
|
6. Appropriate ICD therapy Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for Patients with Clinically Manifest Disease
Временное ограничение: Through study completion, on average 10 years
|
7. Percentage (%) of ventricular pacing Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for Patients with Clinically Manifest Disease
Временное ограничение: Through study completion, on average 10 years
|
8. AV nodal function Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for Patients with Clinically Silent Disease and Control Patients
Временное ограничение: Through study completion, on average 10 years
|
1. Development of Clinically Manifest CS Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
Соавторы и исследователи
Соавторы
Следователи
- Главный следователь: Pablo Nery, MD, Ottawa Heart Institute Research Corporation
- Главный следователь: Rob Beanlands, MD, Ottawa Heart Institute Research Corporation
- Главный следователь: David Birnie, MD, Ottawa Heart Institute Research Corporation
Публикации и полезные ссылки
Общие публикации
- Weng W, Wiefels C, Chakrabarti S, Nery PB, Celiker-Guler E, Healey JS, Hruczkowski TW, Quinn FR, Promislow S, Medor MC, Spence S, Odabashian R, Alqarawi W, Juneau D, de Kemp R, Leung E, Beanlands R, Birnie D. Atrial Arrhythmias in Clinically Manifest Cardiac Sarcoidosis: Incidence, Burden, Predictors, and Outcomes. J Am Heart Assoc. 2020 Sep;9(17):e017086. doi: 10.1161/JAHA.120.017086. Epub 2020 Aug 20.
- Martineau P, Pelletier-Galarneau M, Juneau D, Leung E, Nery PB, de Kemp R, Beanlands R, Birnie D. Imaging Cardiac Sarcoidosis With FLT-PET Compared With FDG/Perfusion-PET: A Prospective Pilot Study. JACC Cardiovasc Imaging. 2019 Nov;12(11 Pt 1):2280-2281. doi: 10.1016/j.jcmg.2019.06.020. Epub 2019 Aug 14. No abstract available.
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Оцененный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- UOHI-04
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .